Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.

Phase 2

Completed

• Conditions: Urinary Incontinence, Stress

• Registration Number: NCT00141128
• Lead Sponsor: Pfizer

Brief Summary

SS-RBX will be used to evaluate pharmacodynamic changes in urethral function using a novel methodology

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-08-29
• Study First Submitted QC: 2005-08-31
• Study First Posted: 2005-09-01
• Study Start: 2005-12
• Study Completion: 2006-06
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-31
• Last Update Posted: 2011-06-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 18

Inclusion Criteria

• Female
• Stress urinary incontinence

Exclusion Criteria

• Bladder outflow obstruction
• Neurological disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
To assess the utility of urethral reflectometry in the detection of pharmacologically induced pressure changes in the female urethra.

Secondary Outcome Measures

Name	Time	Method
To assess the effect of [S,S]-Reboxetine on urethral function in women with SUI.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇩🇰 Glostrup, Denmark